Ekso Bionics (EKSO)
(Real Time Quote from BATS)
$1.30 USD
+0.05 (4.00%)
Updated Apr 29, 2024 03:40 PM ET
3-Hold of 5 3
C Value B Growth C Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
EKSO 1.30 +0.05(4.00%)
Will EKSO be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for EKSO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for EKSO
Ekso Bionics (EKSO) Reports Q4 Loss, Tops Revenue Estimates
Here's Why Ekso Bionics (EKSO) Is a Great 'Buy the Bottom' Stock Now
EKSO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Best Momentum Stocks to Buy for January 31st
New Strong Buy Stocks for January 31st
Ekso Bionics (EKSO) Reports Q3 Loss, Tops Revenue Estimates
Other News for EKSO
Ekso Bionics to Report First Quarter 2024 Financial Results on April 29, 2024
Ekso Bionics Receives Final Payment Determination for Medicare Reimbursement from the Centers for Medicare & Medicaid Services (CMS) for Ekso Indego Personal
Ekso Bionics receives payment determination for medical reimbursement from CMS
Cognition Therapeutics And 2 Other Stocks Under $2 Insiders Are Buying
Why SOPHiA GENETICS Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session